Rare Pediatric Diseases
HER2+ Breast Cancer
ABOUT OUR PARKINSON'S DISEASE PRODUCT
AIP-201: PET Imaging Agent for Parkinson’s Disease (PD)
We've developed a PET imaging agent that allows neurologists the ability to differentiate Parkinson's from essential tremor and other movement disorders.
AIP-201 is a PET imaging agent indicated for striatal dopamine transporter visualization.
PET scans take about 90 minutes
SPECT scans take about 3-6 hours
PET offers sensitivity two to three orders of magnitude higher than SPECT
Fluorine-18, a PET radioisotope, results in
one-half the radiation
of Iodine-123, a SPECT radioisotope
69-year-old female patient with essential tremor
AIP-201 is not approved by the U.S. Food and Drug Administration and is not marketed in the U.S.
A New Drug Application has been submitted to the FDA.